Contract Research Organizations (CROs) have become indispensable partners in pharmaceutical development, with the global CRO market set to reach $93 billion in 2026 as companies increasingly outsource R&D to accelerate timelines and control costs. These external service providers handle everything from preclinical testing to regulatory compliance, but the industry is undergoing a fundamental shift driven by artificial intelligence adoption and changing sponsor expectations.

What Exactly Do Contract Research Organizations Do?

CROs provide specialized support across the entire drug development pipeline. Unlike Contract Development and Manufacturing Organizations (CDMOs), which focus on producing the actual drug, CROs concentrate on the research and development side of the process. They've become essential because pharmaceutical and biotech companies need to move faster while managing costs, and outsourcing specific functions allows them to tap into specialized expertise without building those capabilities in-house.

The range of services CROs offer has expanded significantly. Companies can now outsource preclinical testing, clinical trial management, data analysis, regulatory affairs, drug safety monitoring, and medical writing. This breadth of services means sponsors can choose exactly which functions they want to hand off, rather than committing to a single full-service vendor for everything.

How Are CROs Adopting AI to Transform Drug Development?

• AI-Powered Decision Support: Sponsors increasingly expect CRO partners to deliver data-driven decision support throughout development, not just handle execution. This includes using AI for protocol design, feasibility modeling, patient targeting, and automated data review.
• Rapid Market Growth: The AI-in-CRO-services segment is now tracked as its own market, valued at roughly $14.55 billion in 2026 and projected to grow to $18.45 billion by 2031 at an 18.45% compound annual growth rate. This is more than double the growth rate of the broader CRO market.
• Regulatory Alignment: The FDA issued draft guidance on AI use in clinical development in January 2025, establishing an early compliance pathway for AI-enabled trial tools. The finalized ICH E6(R3) Good Clinical Practice guideline, adopted in January 2025, reflects this shift toward technology-enabled trial oversight.

Despite the rapid pace of AI adoption, efficiency gains are currently showing up primarily in CRO profit margins rather than dramatically reshaping the outsourcing economics. The labor-based outsourcing model is evolving gradually rather than being disrupted overnight, according to analysis of CRO earnings trends.

What Is the FSP 2.0 Model and Why Does It Matter?

Many sponsors are moving away from traditional full-service outsourcing toward Functional Service Provider (FSP) arrangements, where a CRO supplies dedicated functional teams such as biostatistics, data management, or clinical monitoring that integrate directly into the sponsor's own processes. This hybrid approach gives companies more flexibility to scale specific functions up or down without committing to a single vendor.

An emerging "FSP 2.0" model is expected to dominate in 2026, in which these partnerships rely on centralized, data-savvy teams using AI-enhanced workflows rather than pure staff augmentation. This represents a meaningful shift in how sponsors and CROs work together, moving from a traditional outsourcing relationship to a more integrated, technology-enabled partnership.

How Should Pharma Companies Evaluate CRO Partnerships?

• Service Specialization: There is rising demand for CROs with expertise in specialized therapeutic areas such as oncology, neurology, rare diseases, and gene therapies. Procurement teams should assess whether a CRO has deep experience in their specific therapeutic focus.
• Technology Capabilities: CROs are adopting advanced technologies including artificial intelligence, machine learning, and big data analytics to enhance efficiency, data quality, and decision-making capabilities. Evaluate whether a potential partner has invested in these tools and can demonstrate their impact.
• Regulatory Expertise: The pharmaceutical industry is subject to stringent regulatory frameworks, so CROs must maintain expertise in regulatory affairs and ensure compliance throughout the drug development process. This is especially important given recent FDA guidance on AI use in trials.
• Global Reach: CROs are expanding their presence in emerging markets such as Asia-Pacific and Latin America to tap into growing opportunities and leverage cost advantages. Consider whether a CRO's geographic footprint aligns with your trial needs.

What Market Trends Are Shaping the CRO Industry in 2026?

The CRO market is experiencing sustained growth, with the global market calculated at $77 billion in 2025 and predicted to increase to $82.90 billion in 2026, reaching approximately $158.58 billion by 2035, growing at a compound annual growth rate of 7.49% from 2026 to 2035. Clinical research services are expected to lead the market with roughly 41% share in 2026, and Phase I studies are projected to capture the largest phase-specific share at around 48%, reflecting continued growth in first-in-human testing volumes.

Decentralized clinical trials (DCTs), which use remote monitoring, telehealth visits, and local or home-based sample collection, have moved from experimental pilots to a standard sponsor expectation. DCT adoption is projected to grow 15 to 20% annually through 2026, driven by patient demand for convenience and CRO investment in remote-trial technology. Most therapeutic areas are expected to incorporate at least some degree of decentralized methodology going forward, supported by updated FDA guidance on conducting trials with decentralized elements.

The regulatory landscape is also shifting. The BIOSECURE Act, signed into U.S. law in December 2025 as part of the National Defense Authorization Act, represents one of the most significant 2026 developments for pharma procurement teams, affecting how companies source CRO services and manage supply chain risk.

For pharmaceutical and biotech companies, the message is clear: the CRO landscape is becoming more sophisticated, more technology-driven, and more essential to competitive drug development. Procurement teams that understand these trends and can evaluate CRO partners on AI capabilities, therapeutic specialization, and regulatory expertise will be better positioned to accelerate their development timelines while managing costs effectively.